 |
|
|
| |
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study
|
| |
| |
EACS 2021 Oct 27-30
J Mallolas,1 V Esposito,2 L Hocqueloux,3 JS Lambert,4,5 I Levy,6,7 C Wyen,8 B van Welzen,9 A Ustianowski,10 S Schreiber,11 D Thorpe,12 M Heinzkill,11 A Marongiu,12 R Haubrich,13 H Loemba14
1HIV Unit, Hospital Clinic of Barcelona, Barcelona, Spain; 2Immunodeficiencies and Gender Related Infectious Diseases Unit D, Cotugno Hospital, Naples, Italy; 3Orléans Regional Hospital, Orléans, France; 4Mater Misericordiae University Hospital, Dublin, Ireland; 5UCD, Dublin, Ireland; 6Sheba Medical Center, Tel Hashomer Hospital, Ramat Gan, Israel; 7Sackler Medical School, Tel Aviv University, Tel Aviv, Israel; 8Praxis am Erbertplatz, Cologne, Germany; 9University Medical Centre Utrecht, Utrecht, Netherlands; 10North Manchester General Hospital, Manchester, UK; 11Gilead Sciences GmbH, Munich, Germany; 12Gilead Sciences Europe Ltd, Stockley Park, UK; 13Gilead Sciences, Foster City, USA; 14Montfort Hospital, Ottawa, Canada.
|
| |
|
|
|
|
|
